22 results on '"Chengbo Han"'
Search Results
2. Pretreatment pulmonary tumor necrosis is a promising prognostic imaging biomarker for first-line anti-PD-1/PD-L1 therapy in advanced lung squamous cell carcinoma: a multi-institutional, propensity score-matching cohort analysis
- Author
-
Qiaofeng Zhong, Longfeng Zhang, Lin Wu, Jun Zhao, Jianguo Sun, Yong Fang, Jin Zhou, Qian Chu, Yihong Shen, Zhenzhou Yang, Lijin Chen, Meijuan Huang, Xiaoyan Lin, Zhenhua Liu, Peng Shen, Zhijie Wang, Xin Wang, Huijuan Wang, Chengbo Han, Anwen Liu, Hongmei Zhang, Feng Ye, Wen Gao, Fang Wu, Zhengbo Song, Shengchi Chen, Chengzhi Zhou, Dingzhi Huang, Qiuyu Zhang, Xinlong Zheng, Xiaobin Zheng, Qian Miao, Kan Jiang, Zihua Zou, Yiquan Xu, Shiwen Wu, Haibo Wang, Yaping Hong, Tao Lu, Chao Li, Cheng Huang, Chuanben Chen, and Gen Lin
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Background: Tumor necrosis (TN) is a common feature in lung squamous cell carcinoma (LSCC), which could provide useful predictive and prognostic information. Objectives: This study aimed to investigate the effect of pretreatment pulmonary TN (PTN) on the prognosis of first-line anti-programmed cell death 1 (PD-1)/PD ligand 1 (PD-L1) inhibitor in advanced LSCC. Design: We conducted a retrospective study to analyze the association between the presence of PTN and clinical outcomes in advanced LSCC patients treated with anti-PD-1/PD-L1 inhibitors. Methods: Data from 240 eligible patients were collected from 27 hospitals across China between 2016 and 2020. The presence of PTN was assessed using contrast-enhanced chest computed tomography (CT) imaging at baseline. We utilized the Cox proportional-hazards regression model to analyze the association between PTN and clinical outcomes. In addition, to account for potential confounding factors and ensure comparability between groups, we employed propensity score-matching (PSM) analysis. Results: In the overall patient cohort, the presence of PTN was 39.6%. The median follow-up duration was 20.3 months. The positive PTN group exhibited a notably inferior median progression-free survival (PFS; 6.5 months vs 8.6 months, p = 0.012) compared to the negative PTN group. Within the Cox proportional-hazards regression model, PTN emerged as an independent predictor of unfavorable PFS (hazard ratio (HR) = 1.354, 95% confidence interval (CI): 1.002–1.830, p = 0.049). After PSM, the median PFS for the positive PTN group (6.5 months vs 8.0 months, p = 0.027) remained worse than that of the negative PTN group. Multivariate analyses also further underscored that the presence of PTN independently posed a risk for shorter PFS (HR = 1.494, 95% CI: 1.056–2.112, p = 0.023). However, no statistically significant difference in overall survival was observed between the two groups. Conclusion: Our study suggests that the presence of PTN on baseline contrast-enhanced chest CT is a potential negative prognostic imaging biomarker for the outcome of anti-PD-1/PD-L1 inhibitor therapy in advanced LSCC. Further studies are warranted to validate these findings and explore the underlying mechanisms.
- Published
- 2024
- Full Text
- View/download PDF
3. Rechallenge of immune checkpoint inhibitors in advanced non‐small cell lung cancer
- Author
-
Gen Lin, Zhijie Wang, Qian Chu, Yi Hu, Dingzhi Huang, Jun Wang, Fan Yang, Wenzhao Zhong, Chengzhi Zhou, Bo Zhu, Xinghao Ai, Baoshan Cao, Yabing Cao, Mingqiu Chen, Xiaohui Chen, Tianqing Chu, Jianchun Duan, Yun Fan, Yong Fang, Shuitu Feng, Weineng Feng, Hui Guo, Chengbo Han, Yong He, Shaodong Hong, Jie Hu, Meijuan Huang, Yan Huang, Da Jiang, Kan Jiang, Richeng Jiang, Bo Jin, Shi Jin, Jisheng Li, Min Li, Ziming Li, Chao Li, Jie Lin, Anwen Liu, Si‐Yang Maggie Liu, Liu Yutao, Zhefeng Liu, Zhe Liu, Zhenhua Liu, Zhentian Liu, Zhigang Liu, Yuping Lu, Tangfeng Lv, Zhiyong Ma, Qian Miao, Min Peng, Xingxiang Pu, Xiu Bao Ren, Jianzhen Shan, Jinlu Shan, Peng Shen, Bo Shen, Meiqi Shi, Yong Song, Zhengbo Song, ChunXia Su, Jianguo Sun, Panwen Tian, Jinliang Wang, Feng Wang, Huijuan Wang, Jialei Wang, Qian Wang, Wenxian Wang, Yan Wang, Lin Wu, Fang Wu, Yang Xia, Congying Xie, Conghua Xie, Tao Xin, Jianping Xiong, Haipeng Xu, Song Xu, Yiquan Xu, Bin Xu, Chunwei Xu, Xiaolong Yan, Zhenzhou Yang, Wenxiu Yao, Yao Yu, Ye Feng, Zongyang Yu, Yongfeng Yu, Dongsheng Yue, Haibo Zhang, HongMei Zhang, Li Zhang, Longfeng Zhang, Qiuyu Zhang, Tongmei Zhang, Bicheng Zhang, Jun Zhao, Mingfang Zhao, Xiaobin Zheng, Qiaofeng Zhong, Jin Zhou, Penghui Zhou, Zhengfei Zhu, Juntao Zou, and Zihua Zou
- Subjects
ICI ,NSCLC ,re‐challenge ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Immune checkpoint inhibitor (ICI) rechallenge in non‐small cell lung cancer (NSCLC) is a promising therapeutic strategy. The situation for ICI rechallenge can be divided into three categories: adverse events (AEs); resistance to ICIs, and rechallenge becomes compulsive because of tumor relapse while the patients had completed a 2 year course of immunotherapy. However, these categories are still controversial and should be explored further. Through voting at the 6th Straits Summit Forum on Lung Cancer, in this study we summarize the consensus of 147 experts in ICI rechallenges. A total of 97.74% experts agreed to rechallenge; 48.87% experts rechallenge with the original drug, and the others rechallenge with a different drug; 40.3% agreed to rechallenge directly after progression; 88.06% experts agreed to ICI rechallenge with a combination regimen; and factors such as previous performance status score, PD‐1 expression, and age should also be considered. Understanding the the clinical studies in ICI rechallenge could bring us one step closer to understanding the consensus. In patients with advanced NSCLC who have suffered recurrent or distant metastasis after immunotherapy, the option of rechallenge with ICIs is a promising treatment option.
- Published
- 2024
- Full Text
- View/download PDF
4. Clinical definition of secondary resistance to immunotherapy in non‐small cell lung cancer
- Author
-
Dingzhi Huang, Gen Lin, Qian Chu, Yi Hu, Jun Wang, Zhijie Wang, Fan Yang, Wenzhao Zhong, Chengzhi Zhou, Bo Zhu, Xinghao Ai, Baoshan Cao, Yabing Cao, Mingqiu Chen, Xiaohui Chen, Tianqing Chu, Jianchun Duan, Yun Fan, Yong Fang, Shuitu Feng, Weineng Feng, Hui Guo, Chengbo Han, Yong He, Shaodong Hong, Jie Hu, Meijuan Huang, Yan Huang, Da Jiang, Kan Jiang, Richeng Jiang, Bo Jin, Shi Jin, Jisheng Li, Min Li, Ziming Li, Chao Li, Jie Lin, Anwen Liu, Si‐Yang Maggie Liu, Yutao Liu, Zhefeng Liu, Zhe Liu, Zhenhua Liu, Zhentian Liu, Zhigang Liu, Yuping Lu, Tangfeng Lv, Zhiyong Ma, Qian Miao, Min Peng, Xingxiang Pu, Xiu Bao Ren, Jianzhen Shan, Jinlu Shan, Peng Shen, Bo Shen, Meiqi Shi, Yong Song, Zhengbo Song, ChunXia Su, Jianguo Sun, Panwen Tian, Jinliang Wang, Feng Wang, Huijuan Wang, Jialei Wang, Qian Wang, Wenxian Wang, Yan Wang, Lin Wu, Fang Wu, Yang Xia, Congying Xie, Conghua Xie, Tao Xin, Jianping Xiong, Haipeng Xu, Song Xu, Yiquan Xu, Bin Xu, Chunwei Xu, Xiaolong Yan, Zhenzhou Yang, Wenxiu Yao, Yao Yu, Ye Feng, Zongyang Yu, Yongfeng Yu, Dongsheng Yue, Haibo Zhang, HongMei Zhang, Li Zhang, Longfeng Zhang, Qiuyu Zhang, Tongmei Zhang, Bicheng Zhang, Jun Zhao, Mingfang Zhao, Xiaobin Zheng, Fengqiao Zhong, Jin Zhou, Penghui Zhou, Zhengfei Zhu, Juntao Zou, and Zihua Zou
- Subjects
immunotherapy ,NSCLC ,secondary resistance ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Immune checkpoint inhibitors (PD‐1/PD‐L1 and CTLA‐4 blockade) have revolutionized the treatment landscape in non‐small cell lung cancer (NSCLC). Secondary resistance to immunotherapy (IO), which poses a substantial challenge in clinical settings, occurs in several initial responders. Currently, new treatment approaches have been extensively evaluated in investigational studies for these patients to tackle this difficult problem; however, the lack of consistency in clinical definition, uniform criteria for enrollment in clinical trials, and interpretation of results remain significant hurdles to progress. Thus, our expert panel comprehensively synthesized data from current studies to propose a practical clinical definition of secondary resistance to immunotherapy in NSCLC in metastatic and neoadjuvant settings. In addition to patients who received IO alone (including IO‐IO combinations), we also generated a definition for patients treated with chemotherapy plus IO. This consensus aimed to provide guidance for clinical trial design and facilitate future discussions with investigators. It should be noted that additional updates in this consensus are required when new data is available.
- Published
- 2023
- Full Text
- View/download PDF
5. Sintilimab, stereotactic body radiotherapy and granulocyte–macrophage colony stimulating factor as second-line therapy for advanced non-small cell lung cancer: safety run-in results of a multicenter, single-arm, phase II trial
- Author
-
Jianjiao Ni, Yue Zhou, Lin Wu, Xinghao Ai, Xiaorong Dong, Qian Chu, Chengbo Han, Xiaofei Wang, and Zhengfei Zhu
- Subjects
Sintilimab ,Stereotactic body radiotherapy (SBRT) ,Granulocyte–macrophage colony stimulating factor (GM-CSF) ,Non-small cell lung cancer (NSCLC) ,Treatment-related adverse event (TRAE) ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Objectives The SWORD trial is the first multicenter, single arm, phase II study assessing the safety and efficacy of a PD-1 inhibitor (Sintilimab), stereotactic body radiotherapy (SBRT) and granulocyte–macrophage colony stimulating factor (GM-CSF) in advanced non-small cell lung cancer (NSCLC) without sensitizing driver mutations. A safety run-in phase was conducted to determine the tolerability of the experimental treatment. Materials and methods Twenty metastatic NSCLC patients who failed first-line chemotherapy were enrolled, and they received SBRT (8 Gy × 3) to one lesion, followed by Sintilimab (200 mg d1, every 3 weeks, until disease progression, unacceptable toxicity, or up to 35 cycles) and GM-CSF (125 μg/m2 d1-d14, cycle 1) within 2 weeks after SBRT. In addition, blood and tissue samples were serially collected for translational research. Results Median age of the patients was 61 and all of them had more than 5 lesions at baseline. The sites of SBRT included lung (n = 11), mediastinal lymph node (n = 5), liver (n = 1), abdominal lymph node (n = 1), pleural nodule (n = 1) and vertebra (n = 1). No patients had dose-limiting toxicities (DLTs) and 18 patients experienced treatment-related adverse event (TRAE). The most common TRAEs were fatigue (50%), fever (30%), and ostealgia (20%), and they all were grade 1. Only 2 grade 3 TRAEs were observed, including elevation of liver enzymes in one and transient acute heart failure in another. No grade 4 or 5 AE was observed. Conclusion Sintilimab, SBRT and GM-CSF for advanced NSCLC is safe with manageable TRAEs and the trial continues to recruit participants. Trial registration ClinicalTrials.gov, NCT04106180. Registered 26 September 2019, SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC-Tabular View-ClinicalTrials.gov.
- Published
- 2021
- Full Text
- View/download PDF
6. Impact of Drp1-Mediated Mitochondrial Dynamics on T Cell Immune Modulation
- Author
-
Jun Song, Xiaofang Yi, Ruolin Gao, Li Sun, Zhixuan Wu, Shuling Zhang, Letian Huang, Chengbo Han, and Jietao Ma
- Subjects
dynamin-related protein 1 ,immunotherapy ,mitochondrial dynamics ,T cell exhaustion ,tumor microenvironment ,Immunologic diseases. Allergy ,RC581-607 - Abstract
In recent years, various breakthroughs have been made in tumor immunotherapy that have contributed to prolonging the survival of tumor patients. However, only a subset of patients respond to immunotherapy, which limits its use. One reason for this is that the tumor microenvironment (TME) hinders the migration and infiltration of T cells and affects their continuous functioning, resulting in an exhausted phenotype. Therefore, clarifying the mechanism by which T cells become exhausted is of significance for improving the efficacy of immunotherapy. Several recent studies have shown that mitochondrial dynamics play an important role in the immune surveillance function of T cells. Dynamin-related protein 1 (Drp1) is a key protein that mediates mitochondrial fission and maintains the mitochondrial dynamic network. Drp1 regulates various activities of T cells in vivo by mediating the activation of a series of pathways. In addition, abnormal mitochondrial dynamics were observed in exhausted T cells in the TME. As a potential target for immunotherapy, in this review, we describe in detail how Drp1 regulates various physiological functions of T cells and induces changes in mitochondrial dynamics in the TME, providing a theoretical basis for further research.
- Published
- 2022
- Full Text
- View/download PDF
7. Combination of Radiation Therapy and Immunotherapy for Non-small Cell Lung Cancer: Peer Exchange on Frontier Academic Topics
- Author
-
Radiotherapy-Immunotherapy Discussion Group, Xinghao AI, Yong CAI, Qian CHU, Chengbo HAN, You LU, Songbing QIN, Lin WU, Conghua XIE, Zhiyong YUAN, Wenzhao ZHONG, Xiaoxia ZHU, Joe Y. CHANG, and Zhengfei ZHU
- Subjects
immune checkpoint inhibitors ,neoplasms ,radiotherapy ,immunotherapy ,adverse effects ,toxicity ,mixed responses ,brain metastases ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Lung cancer is the leading cause of cancer death worldwide as well as in China. For many years, conventional oncologic treatments such as surgery, chemotherapy, and radiotherapy (RT) have dominated the field of non-small cell lung cancer (NSCLC). The recent introduction of immunotherapy in clinical practice, led to a paradigm shift in lung cancer as in many other solid tumors. Recent pre-clinical and clinical data have shown RT may also modify antitumor immune responses through induction of immunogenic cell death and reprogramming of the tumor microenvironment. This has led many to reexamine RT as a partner therapy to immuno-oncology treatments and investigate their potential synergy in an exponentially growing number of clinical trials. Clinical trials combining radiotherapy and immunotherapy are attracting major attention, experts were invited to discuss frontier and controversial academic topics: (1) Recent developments of clinical synergy between radiation and immune checkpoint inhibitors (ICIs) in the treatment of NSCLC; (2) Will immunotherapy and radiotherapy increase the toxicity risk for cancer patients; (3) How to cope the mixed responses/disassociated responses phenomenon in checkpoint inhibition therapy to NSCLC with local ablative therapy; (4) Combining radiotherapy and immunotherapy in the treatment of NSCLC brain metastases.
- Published
- 2020
- Full Text
- View/download PDF
8. Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review
- Author
-
Yijia Guo, Jun Song, Yanru Wang, Letian Huang, Li Sun, Jianzhu Zhao, Shuling Zhang, Wei Jing, Jietao Ma, and Chengbo Han
- Subjects
non-small cell lung cancer ,concurrent genetic alteration ,epidermal growth factor receptor tyrosine kinase inhibitors ,PD-L1 expression ,BIM polymorphism ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) greatly improve the survival and quality of life of non-small cell lung cancer (NSCLC) patients with EGFR mutations. However, many patients exhibit de novo or primary/early resistance. In addition, patients who initially respond to EGFR-TKIs exhibit marked diversity in clinical outcomes. With the development of comprehensive genomic profiling, various mutations and concurrent (i.e., coexisting) genetic alterations have been discovered. Many studies have revealed that concurrent genetic alterations play an important role in the response and resistance of EGFR-mutant NSCLC to EGFR-TKIs. To optimize clinical outcomes, a better understanding of specific concurrent gene alterations and their impact on EGFR-TKI treatment efficacy is necessary. Further exploration of other biomarkers that can predict EGFR-TKI efficacy will help clinicians identify patients who may not respond to TKIs and allow them to choose appropriate treatment strategies. Here, we review the literature on specific gene alterations that coexist with EGFR mutations, including common alterations (intra-EGFR [on target] co-mutation, TP53, PIK3CA, and PTEN) and driver gene alterations (ALK, KRAS, ROS1, and MET). We also summarize data for other biomarkers (e.g., PD-L1 expression and BIM polymorphisms) associated with EGFR-TKI efficacy.
- Published
- 2020
- Full Text
- View/download PDF
9. Research Advances of Pan-negative Type of Non-small Cell Lung Cancer
- Author
-
Li SUN, Zhicheng XIONG, and Chengbo HAN
- Subjects
Lung neoplasms ,Driver gene ,Pan-negative ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
In recent years, series of driver genes, such as EGFR, KRAS/NRAS, BRAF, PIK3CA, ALK and ROS1 and so on, have been found in non-small cell lung cancer (NSCLC) one after another with the development of molecular detecting technology. Targeted drugs bring benefits for these NSCLC patients with driver gene variations. However, some NSCLC did not have any known driver gene variations; we called it pan-negative lung cancer. In this paper, we summarize the concept, clinical pathological characteristics, the epidemiological characteristics, treatment and prognosis of pan-negative NSCLC.
- Published
- 2018
- Full Text
- View/download PDF
10. Comparison of EGFR and KRAS Status between Primary Non-small Cell Lung Cancer and Corresponding Metastases: A Systematic Review and meta-analysis
- Author
-
Chengbo HAN, Huawei ZOU, Jietao MA, Yang ZHOU, and Jianzhu ZHAO
- Subjects
Lung neoplasms ,Primary tumor ,Metastases ,Epidermal growth factor receptor ,KRAS ,Mutation ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Background and objective Epidermal growth factor receptor (EGFR) and KRAS status were particularly critical for the choice of first-line targeted therapy of non-small cell lung cancer (NSCLC), while the primary tumor and metastases might be different in the EGFR and KRAS gene status. The aim of this pooled analysis is to compare EGFR and KRAS status in matching primary NSCLC and metastases and further to guide clinical practice. Methods Systematic computerized searches of the Pubmed and Medline databases (up to May 10, 2010) meeting specified search criteria were performed, followed by a further screening according to inclusive and exclusive criteria. Results Fourteen articles were selected into the final meta-analysis with paired primary and metastatic cases of 598. Expression level of EGFR protein and mutation frequency of KRAS gene in primary tumors were higher than that in metastases, relative risk (RR)=1.13 (95%CI: 0.98-1.31, P=0.09) and RR=1.39 (95%CI: 0.95-2.03, P=0.09), respectively. EGFR gene copy number in metastases was higher than that in primary tumor, RR=0.74 (95%CI: 0.53-1.02, P=0.06). There was no statistically significant difference of EGFR mutation frequency in primary tumors and metastases (P=0.31). The discordant rate in primary and metastases was 17.09% for EGFR mutation, 27.07% for EGFR amplification, 27.84% for EGFR protein expression and 25.91% for KRAS mutation. Conclusion The systematic analysis showed that the EGFR mutation status in primary lung cancer and corresponding metastases was more stable than KRAS gene. KRAS mutation in primary lung cancerous foci seems to better reflect systemically cancerous genetic characteristics of KRAS gene. Determination of KRAS gene status based merely on metastatic foci might lead to more resistant selections of EGFR tyrosine kinase inhibitor (TKI) therapy. Combined detection of EGFR and KRAS mutation from primary NSCLC foci might serve as a better predictive biomarker for anti-EGFR targeted therapy.
- Published
- 2010
11. Expression of Mitochondrial Transcripts in Gastric MGC803 Cell Line Subjected by Hypoxia
- Author
-
Chengbo HAN, Jietao MA, and Huawei ZHOU
- Subjects
gastric carcinoma ,DNA ,mitochondrial ,hypoxia ,irradiation ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
OBJECTIVE To determine the transcriptional expression of mitochondrial genome (mtDNA) in MGC803 cell lines subjected by various time-phase hypoxic dispositions, and further to discuss the influence of mtDNA transcripts on hypoxic resistance to irradiation. METHODS The MGC803 cells exposed to anoxic environment were divided into control group (0 h), hypoxic group (2 h, 8 h, 16 h, 24 h) and irradiated group after exposing the hypoxia. RT-PCR was applied to detect the transcripts of cytochrome oxidase subunit I (COI), NADH dehydrogenase subunit 4 (ND4), ND5, cytochrome b (cyt-b) and ATPase6 (ATP-6) in MGC803 cell lines at various time-phases of hypoxic, and after X-ray irradiation. Flow cytometry and colony formation assay were conducted to evaluate the cell cycle phase and survival fraction. RESULTS COI and ND4 transcripts of MGC803 cell lines were influenced remarkably by hypoxia. COI transcripts were decreased remarkably with the elongation time of exposing the hypoxic, and reduced to one fourth of its original amount of pre-hypoxia 24 h after exposing the hypoxia. ND4 transcripts were increased initially, and elevated to two folds 8 h after exposing the hypoxia, and then reduced to one second 24 h after exposing the hypoxia. Hypoxia resulted in G1 phase blockage, especially after hypoxia for 16 h. The survival fraction of MGC803 cells exposing the hypoxia in irradiated group showed that as the time of exposing the hypoxic before irradiation is prolonged, the survival fraction of MGC803 cells may have an elevated tendency. CONCLUSION The tumor cells with lower expression levels of the COI and the ND4 after exposing the hypoxic have stronger resistance to the radiation, which indicates that increasing the expression levels of the COI and the ND4 might be advantageous to enhance the sensitivity of hypoxic tumor cells to the radiotherapy.
- Published
- 2009
- Full Text
- View/download PDF
12. [Combination of Radiation Therapy and Immunotherapy for Non-small Cell Lung Cancer: Peer Exchange on Frontier Academic Topics]
- Author
-
Xinghao, Ai, Yong, Cai, Qian, Chu, Chengbo, Han, You, Lu, Songbing, Qin, Lin, Wu, Conghua, Xie, Zhiyong, Yuan, Wenzhao, Zhong, Xiaoxia, Zhu, Joe Y, Chang, and Zhengfei, Zhu
- Subjects
Lung Neoplasms ,Radiotherapy ,Toxicity ,Adverse effects ,综述 ,Brain metastases ,Review ,毒性 ,Combined Modality Therapy ,免疫治疗 ,脑转移 ,Immune checkpoint inhibitors ,Treatment Outcome ,放疗 ,不良反应 ,Mixed responses ,Carcinoma, Non-Small-Cell Lung ,混合反应 ,Neoplasms ,Humans ,免疫检查点抑制剂 ,Immunotherapy ,Safety ,肿瘤 - Abstract
Lung cancer is the leading cause of cancer death worldwide as well as in China. For many years, conventional oncologic treatments such as surgery, chemotherapy, and radiotherapy (RT) have dominated the field of non-small cell lung cancer (NSCLC). The recent introduction of immunotherapy in clinical practice, led to a paradigm shift in lung cancer as in many other solid tumors. Recent pre-clinical and clinical data have shown RT may also modify antitumor immune responses through induction of immunogenic cell death and reprogramming of the tumor microenvironment. This has led many to reexamine RT as a partner therapy to immuno-oncology treatments and investigate their potential synergy in an exponentially growing number of clinical trials. Clinical trials combining radiotherapy and immunotherapy are attracting major attention, experts were invited to discuss frontier and controversial academic topics: (1) Recent developments of clinical synergy between radiation and immune checkpoint inhibitors (ICIs) in the treatment of NSCLC; (2) Will immunotherapy and radiotherapy increase the toxicity risk for cancer patients; (3) How to cope the mixed responses/disassociated responses phenomenon in checkpoint inhibition therapy to NSCLC with local ablative therapy; (4) Combining radiotherapy and immunotherapy in the treatment of NSCLC brain metastases.【中文题目:放疗联合免疫治疗非小细胞肺癌:前沿学术问题专家交流共识】 【中文摘要:肺癌是目前导致全球和中国癌症患者死亡的主要瘤种。多年来,常规的肿瘤治疗方法,如手术、化疗和放疗一直主导着非小细胞肺癌(non-small cell lung cancer, NSCLC)治疗领域。临床实践中引入免疫疗法使肺癌的治疗与其他实体瘤一样发生了根本性转变。最新临床前和临床数据表明,放疗可以通过诱导免疫原性细胞死亡和重新编程肿瘤微环境促进抗肿瘤免疫反应。研究者开始重新审视放疗作为免疫治疗的联合疗法,导致研究其潜在协同作用的临床试验数量呈指数级增长。放疗联合免疫治疗的临床试验引起了医疗界的广泛关注,会议邀请专家交流前沿及争议学术问题:①放疗联合免疫检查点抑制剂治疗NSCLC最新进展;②放疗联合免疫治疗是否显著增加毒性;③免疫检查点抑制剂治疗后出现的混合反应及局部治疗的干预价值;④放疗联合免疫治疗脑转移瘤的机制和进展。】 【中文关键词:免疫检查点抑制剂;肿瘤;放疗;免疫治疗;不良反应;毒性;混合反应;脑转移】.
- Published
- 2020
13. Real-world EGFR testing in patients with stage IIIB/IV non-small-cell lung cancer in North China: A multicenter, non-interventional study
- Author
-
Ying Cheng, Yan Wang, Jun Zhao, Yunpeng Liu, Hongjun Gao, Kewei Ma, Shucai Zhang, Hua Xin, Jiwei Liu, Chengbo Han, Zhitu Zhu, Jun Chen, Fugang Wen, Junling Li, Jie Zhang, Zhendong Zheng, Zhaoxia Dai, Hongmei Piao, Xiaoling Li, Yinyin Li, Min Zhong, Rui Ma, Yongzhi Zhuang, Yuqing Xu, Zhuohui Qu, Haibo Yang, Chunxia Pan, Fan Yang, Daxin Zhang, and Bing Li
- Subjects
0301 basic medicine ,Pulmonary and Respiratory Medicine ,Oncology ,medicine.medical_specialty ,medicine.drug_class ,medicine.medical_treatment ,Tyrosine-kinase inhibitor ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Biopsy ,Medicine ,In patient ,Epidermal growth factor receptor ,Lung cancer ,Lymph node ,Chemotherapy ,biology ,medicine.diagnostic_test ,business.industry ,General Medicine ,medicine.disease ,respiratory tract diseases ,030104 developmental biology ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,biology.protein ,Adenocarcinoma ,business - Abstract
BACKGROUND Before tyrosine kinase inhibitor (TKI) therapy can be administered in patients with advanced non-small cell lung cancer (NSCLC), EGFR mutation testing is required. However, few studies have evaluated the extent of EGFR testing in real-world practice in China. METHODS A multicenter, observational study of EGFR testing in NSCLC patients in North China was conducted. Treatment-naive patients or those with postoperative recurrent stage IIIB/IV NSCLC were enrolled. The primary objective was EGFR testing rate. Secondary objectives included EGFR mutation status, EGFR testing methods and specimens, factors associated with EGFR testing, and overall survival with or without EGFR testing. RESULTS Overall, 2809 patients with stage IIIB/IV NSCLC were enrolled; 90.78% had adenocarcinoma. The EGFR screening rate was 42.54%. EGFR testing rates were higher in tumor samples obtained by lymph node puncture, and in patients with urban medical insurance, adenocarcinoma, non-smokers, or those located in developed cities (all P < 0.001). The EGFR mutation rate was 46.44%. The most commonly used specimens for EGFR testing were biopsy tumor samples (67.53%). PCR-based methods (72.05%), Sanger sequencing (5.36%), and Luminex liquid chip (5.10%) were the most frequently used testing platforms. Similar positive EGFR mutation rates were achieved with different platforms. TKI therapy was the first-line treatment administered to most EGFR-positive patients (56.22%), and chemotherapy in EGFR-negative patients (84.88%). Overall survival was higher in EGFR-tested than in untested patients (27.50 vs. 19.73 months; P = 0.007). CONCLUSION Real-world EGFR testing rates for NSCLC in North China were relatively low because of clinical and social factors, including medical insurance coverage.
- Published
- 2018
14. Combination of Radiation Therapy and Immunotherapy for Non-small Cell Lung Cancer: Peer Exchange on Frontier Academic Topics.
- Author
-
Xinghao AI, Yong CAI, Qian CHU, Chengbo HAN, You LU, Songbing QIN, Lin WU, Conghua XIE, Zhiyong YUAN, Wenzhao ZHONG, Xiaoxia ZHU, CHANG, Joe Y., and Zhengfei ZHU
- Subjects
BRAIN tumor treatment ,LUNG cancer treatment ,ANTINEOPLASTIC agents ,CANCER patients ,CLINICAL trials ,IMMUNOTHERAPY ,METASTASIS ,RADIOIMMUNOTHERAPY ,TREATMENT effectiveness ,ABLATION techniques ,DRUG administration ,DRUG dosage - Abstract
Lung cancer is the leading cause of cancer death worldwide as well as in China. For many years, conventional oncologic treatments such as surgery, chemotherapy, and radiotherapy (RT) have dominated the field of non-small cell lung cancer (NSCLC). The recent introduction of immunotherapy in clinical practice, led to a paradigm shift in lung cancer as in many other solid tumors. Recent pre-clinical and clinical data have shown RT may also modify antitumor immune responses through induction of immunogenic cell death and reprogramming of the tumor microenvironment. This has led many to reexamine RT as a partner therapy to immuno-oncology treatments and investigate their potential synergy in an exponentially growing number of clinical trials. Clinical trials combining radiotherapy and immunotherapy are attracting major attention, experts were invited to discuss frontier and controversial academic topics: (1) Recent developments of clinical synergy between radiation and immune checkpoint inhibitors (ICIs) in the treatment of NSCLC; (2) Will immunotherapy and radiotherapy increase the toxicity risk for cancer patients; (3) How to cope the mixed responses/disassociated responses phenomenon in checkpoint inhibition therapy to NSCLC with local ablative therapy; (4) Combining radiotherapy and immunotherapy in the treatment of NSCLC brain metastases. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
15. Electronic Control over Attachment and Self-Assembly of Alkyne Groups on Gold
- Author
-
Humberto Terrones, Arthur P. Baddorf, Chengbo Han, Qing Li, Bobby G. Sumpter, Jerry Bernholc, Jieyu Yi, Miguel Fuentes-Cabrera, Zheng Gai, Wenchang Lu, Minghu Pan, and Petro Maksymovych
- Subjects
chemistry.chemical_classification ,Nanostructure ,Macromolecular Substances ,Surface Properties ,Molecular Conformation ,General Engineering ,General Physics and Astronomy ,Alkyne ,Nanotechnology ,Electroplating ,Nanostructures ,chemistry.chemical_compound ,Nanolithography ,Phenylacetylene ,chemistry ,Alkynes ,Materials Testing ,Monolayer ,Surface modification ,Molecule ,General Materials Science ,Gold ,Self-assembly ,Particle Size ,Crystallization - Abstract
Self-assembled monolayers are the basis for molecular nanodevices, flexible surface functionalization, and dip-pen nanolithography. Yet self-assembled monolayers are typically created by a rather inefficient process involving thermally driven attachment reactions of precursor molecules to a metal surface, followed by a slow and defect-prone molecular reorganization. Here we demonstrate a nonthermal, electron-induced approach to the self-assembly of phenylacetylene molecules on gold that allows for a previously unachievable attachment of the molecules to the surface through the alkyne group. While thermal excitation can only desorb the parent molecule due to prohibitively high activation barriers for attachment reactions, localized injection of hot electrons or holes not only overcomes this barrier but also enables an unprecedented control over the size and shape of the self-assembly, defect structures, and the reverse process of molecular disassembly from a single molecule to a mesoscopic length scale. Electron-induced excitation may therefore enable new and highly controlled approaches to molecular self-assembly on a surface.
- Published
- 2012
16. Supramolecular Self-Assembly of π-Conjugated Hydrocarbons via 2D Cooperative CH/π Interaction
- Author
-
Minghu Pan, Miguel Fuentes-Cabrera, Chengbo Han, Bobby G. Sumpter, Petro Maksymovych, Qing Li, Scott R. Horton, Jerry Bernholc, and Wenchang Lu
- Subjects
Models, Molecular ,Macromolecular Substances ,Surface Properties ,Supramolecular chemistry ,General Physics and Astronomy ,law.invention ,Ab initio quantum chemistry methods ,Computational chemistry ,law ,Molecule ,Computer Simulation ,General Materials Science ,Particle Size ,chemistry.chemical_classification ,Chemistry ,Intermolecular force ,General Engineering ,Hydrogen Bonding ,Carbon ,Nanostructures ,Supramolecular polymers ,Models, Chemical ,Chemical physics ,Self-assembly ,Scanning tunneling microscope ,Chirality (chemistry) ,Hydrogen - Abstract
Supramolecular self-assembly on well-defined surfaces provides access to a multitude of nanoscale architectures, including clusters of distinct symmetry and size. The driving forces underlying supramolecular structures generally involve both graphoepitaxy and weak directional nonconvalent interactions. Here we show that functionalizing a benzene molecule with an ethyne group introduces attractive interactions in a 2D geometry, which would otherwise be dominated by intermolecular repulsion. Furthermore, the attractive interactions enable supramolecular self-assembly, wherein a subtle balance between very weak CH/π bonding and molecule-surface interactions produces a well-defined "magic" dimension and chirality of supramolecular clusters. The nature of the process is corroborated by extensive scanning tunneling microscopy/spectroscopy (STM/S) measurements and ab initio calculations, which emphasize the cooperative, multicenter characters of the CH/π interaction. This work points out new possibilities for chemical functionalization of π-conjugated hydrocarbon molecules that may allow for the rational design of supramolecular clusters with a desired shape and size.
- Published
- 2011
17. Decreased mtDNA copy number of gastric cancer: a new tumor marker?
- Author
-
Jie Lin, Fan Li, Chengbo Han, and Xiaosong Wang
- Subjects
Mitochondrial DNA ,medicine ,Cancer ,Decreased mtDNA ,Gastric carcinoma ,Biology ,medicine.disease ,Molecular biology ,Earth-Surface Processes ,Tumor marker ,Staining ,Hypervariable region - Abstract
OBJECTIVE To explore the relationship between mtDNA (mitochondrial DNA) and gastric cancer by comparing the difference of mtDNA copy number in gastric cancers and paracancerous tissues. METHODS The HVl (hypervariable region) and HV2 of the mitochondrial D-loop region from 20 cases of gastric cancer and 20 paracancerous tissues were amplified by PCR with [3-actin serving as a quantitative standard marker. The products were separated by polyacrylamide gel electrophoresis (PAGE) and silver stained in order to compare the difference in mtDNA copy number between gastric cancers and paracancerous tissues. The mtDNA copy number was determined for gastric cancers having various pathological characteristics and the results compared with previous immunohistochemical staining of the tumors. RESULTS There was a significantly quantitative difference in HV1, HV2 (standardized with 13-actin) between gastric cancers and paracancerous tissues ( P 0.05). CONCLUSION The occurrence of gastric cancer was closely associated with decreased mtDNA copy number, which may be a new tumor marker.
- Published
- 2004
18. Pulmonary Artery Invasion, High Dose Radiation, and Overall Survival in Patients with Non-Small Cell Lung Cancer
- Author
-
Chengbo Han, Leslie E. Quint, Randall K. Ten Haken, Feng-Ming Spring Kong, Weili Wang, Martha M. Matuszak, and Jianxin Xue
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,medicine.medical_treatment ,Pulmonary Artery ,Gastroenterology ,Article ,Internal medicine ,medicine.artery ,Carcinoma, Non-Small-Cell Lung ,medicine ,Carcinoma ,Humans ,Radiology, Nuclear Medicine and imaging ,Neoplasm Invasiveness ,Prospective cohort study ,Lung cancer ,Survival analysis ,Aged ,Aged, 80 and over ,Analysis of Variance ,Radiation ,medicine.diagnostic_test ,business.industry ,Radiotherapy Dosage ,Middle Aged ,medicine.disease ,Survival Analysis ,Confidence interval ,Tumor Burden ,Radiation therapy ,Oncology ,Positron emission tomography ,Pulmonary artery ,Female ,Radiology ,Radiotherapy, Conformal ,business ,Tomography, X-Ray Computed - Abstract
Purpose To investigate whether high-dose radiation to the pulmonary artery (PA) affects overall survival (OS) in patients with non-small cell lung cancer (NSCLC). Methods and Materials Patients with medically inoperable/unresectable NSCLC treated with definitive radiation therapy in prospective studies were eligible for this study. Pulmonary artery involvement was defined on the basis of pretreatment chest CT and positron emission tomography/CT fusion. Pulmonary artery was contoured according to the Radiation Therapy Oncology Group protocol 1106 atlas, and dose-volume histograms were generated. Results A total of 100 patients with a minimum follow-up of 1 year for surviving patients were enrolled: 82.0% underwent concurrent chemoradiation therapy. Radiation dose ranged from 60 to 85.5 Gy in 30-37 fractions. Patients with PA invasion of grade ≤2, 3, 4, and 5 had 1-year OS and median survival of 67% and 25.4 months (95% confidence interval [CI] 15.7-35.1), 62% and 22.2 months (95% CI 5.8-38.6), 90% and 35.8 months (95% CI 28.4-43.2), and 50% and 7.0 months, respectively ( P =.601). Two of the 4 patients with grade 5 PA invasion died suddenly from massive hemorrhage at 3 and 4.5 months after completion of radiation therapy. Maximum and mean doses to PA were not significantly associated with OS. The V45, V50, V55, and V60 of PA were correlated significantly with a worse OS ( P 70% or V60 >37% had significantly worse OS (13.3 vs 37.9 months, P P =.04, respectively). Conclusions Grade 5 PA invasion and PA volume receiving more than 45-60 Gy may be associated with inferior OS in patients with advanced NSCLC treated with concurrent chemoradiation.
- Published
- 2014
19. Self-Organized and Cu-Coordinated Surface Linear Polymerization
- Author
-
Jerzy Bernholc, Jonathan R. Owens, Vincent Meunier, Minghu Pan, Bobby G. Sumpter, Peter Maksymovych, Miguel Fuentes-Cabrera, Qing Li, Chengbo Han, and Wenchang Lu
- Subjects
Multidisciplinary ,Computer science ,Depolymerization ,Radical polymerization ,technology, industry, and agriculture ,Conjugated system ,Bioinformatics ,Epitaxy ,Article ,law.invention ,chemistry.chemical_compound ,Phenylacetylene ,chemistry ,Polymerization ,Ab initio quantum chemistry methods ,Chemical physics ,law ,Molecule ,Scanning tunneling microscope ,Spectroscopy ,Nanoscopic scale - Abstract
We demonstrate a controllable surface-coordinated linear polymerization of long-chain poly(phenylacetylenyl)s that are self-organized into a “circuit-board” pattern on a Cu(100) surface. Scanning tunneling microscopy/spectroscopy (STM/S) corroborated by ab initio calculations, reveals the atomistic details of the molecular structure, and provides a clear signature of electronic and vibrational properties of the poly(phenylacetylene)s chains. Notably, the polymerization reaction is confined epitaxially to the copper lattice, despite a large strain along the polymerized chain that subsequently renders it metallic. Polymerization and depolymerization reactions can be controlled locally at the nanoscale by using a charged metal tip. This control demonstrates the possibility of precisely accessing and controlling conjugated chain-growth polymerization at low temperature. This finding may lead to the bottom-up design and realization of sophisticated architectures for molecular nano-devices.
- Published
- 2013
- Full Text
- View/download PDF
20. High Dose to Large Volumes of Pericardium May Be Associated With Radiation-related Pericardial Effusion and Survival in Patients With NSCLC
- Author
-
Jianxin Xue, Martha M. Matuszak, Feng-Ming Spring Kong, James A. Hayman, Chengbo Han, Nan Bi, Gregory P. Kalemkerian, Randal K. Ten Haken, You Lu, and S. Paul
- Subjects
Cancer Research ,medicine.medical_specialty ,Radiation ,Proportional hazards model ,business.industry ,medicine.disease ,Pericardial effusion ,medicine.anatomical_structure ,Oncology ,Internal medicine ,Maximum dose ,medicine ,Cardiology ,Pericardium ,Radiology, Nuclear Medicine and imaging ,Binary logistic regression analysis ,In patient ,business - Abstract
2. The binary logistic regression analysis: Pericardium V50 was positively associated with PCE; while the age, hypertension were negatively with the PCE. • The mean, maximum dose, and V5-V65 for heart were not significantly related to PCE. 3. The cox regression analysis: Pericardium V55 was positively associated with survival; while the radiation tumor dose was negatively with the survival. • The mean, maximum dose, and V5-V65 for heart were not significantly related to survival.
- Published
- 2012
21. Relationship Between Pulmonary Artery Invasion and High-dose Radiation and Overall Survival in Patients With Non-small Cell Lung Cancer
- Author
-
Weili Wang, F.P. Kong, R.K. Ten Haken, James A. Hayman, Chengbo Han, Paul Stanton, Leslie E. Quint, M. Matusak, and Jianxin Xue
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Radiation ,business.industry ,High-dose radiation ,medicine.disease ,Acute toxicity ,surgical procedures, operative ,Pneumothorax ,medicine.artery ,Internal medicine ,Pulmonary artery ,medicine ,Overall survival ,Radiology, Nuclear Medicine and imaging ,In patient ,Radiology ,business ,Lung cancer ,Complication - Abstract
(51 54%), and 40% (38 43%) with SBRT (P > 0.05). In view of acute toxicity, the most frequent complication of RFA is pneumothorax, which occurs in 32% (16 45%) patients, required chest tube insertion in 12% (7 39%) of patients. Conclusions: Local control rate for SBRT is significantly higher than that for RFA, though overall survival seems not significantly different between two treatment groups. However, caution is warranted due to the relatively limited number of RFA and short follow-up time. Author Disclosure: N. Bi: None. K. Shedden: None. X. Zheng: None. W. Wang: None. F. Kong: None.
- Published
- 2012
22. Self-Organized and Cu-Coordinated Surface Linear Polymerization.
- Author
-
Qing Li, Owens, Jonathan R., Chengbo Han, Sumpter, Bobby G., Wenchang Lu, Bernholc, Jerzy, Meunier, V., Maksymovych, Peter, Fuentes-Cabrera, Miguel, and Minghu Pan
- Subjects
MOLECULAR structure ,POLYMERIZATION ,SCANNING tunneling microscopy ,LOW temperatures ,ETHYNYL benzene ,COPPER - Abstract
We demonstrate a controllable surface-coordinated linear polymerization of long-chain poly(phenylacetylenyl)s that are self-organized into a "circuit-board" pattern on a Cu(100) surface. Scanning tunneling microscopy/spectroscopy (STM/S) corroborated by ab initio calculations, reveals the atomistic details of the molecular structure, and provides a clear signature of electronic and vibrational properties of the poly(phenylacetylene)s chains. Notably, the polymerization reaction is confined epitaxially to the copper lattice, despite a large strain along the polymerized chain that subsequently renders it metallic. Polymerization and depolymerization reactions can be controlled locally at the nanoscale by using a charged metal tip. This control demonstrates the possibility of precisely accessing and controlling conjugated chain-growth polymerization at low temperature. This finding may lead to the bottom-up design and realization of sophisticated architectures for molecular nano-devices. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.